Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma

Communications in Clinical Cytometry

Volumn 38, Issue 1, 1999, Pages 24-29

  Perez Simon J A ^a   Valverde, B ^a   Martinez A ^a   Tabernero, D ^a   Almeida, J ^a   Gutierrez, N ^a   San Miguel, Jesús F ^a   Orfao, A ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Drug efflux; MDR1; Multiple myeloma; Prognosis; Rhodamine 123

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALCIUM; CREATININE; LACTATE DEHYDROGENASE; RHODAMINE 123; UREA;

ADULT; AGED; ARTICLE; CHROMOSOME 17; CHROMOSOME 6; CHROMOSOME ABERRATION; CLINICAL ARTICLE; DISEASE COURSE; DRUG ELIMINATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0345435248     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19990215)38:1<24::AID-CYTO4>3.0.CO;2-7     Document Type: Article

References (40)

1. Gregory WM, Richard MA, Malpas JS. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-342.
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97.
3. Barlogie B, Jagannath S, Vesole D.H., Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-793.
4. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988;241:1813.
5. Raaijmakers HGP, Izquierdo MAI, Lokhorst HM, Leeuw C, Belien JAM, Bloem AC, Dekker AW, Scheper RJ, Sonneveld P. Lung resistance related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998;91:1029-1036.
6. Shen H, Paul S, Breuninger LM, Ciaccio PJ, Laing NM, Helt M, Tew KD, Kruh GD. Cellular and in vitro transport of glutathione conjugates by MRP. Biochemistry 1996;35:5719-5725.
7. Sonneveld P, Lokhorst H, Vossebeld P. Drug resistance in multiple myeloma. Sem Hematol 1997;34:34-38.
8. D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989;989:163-177.
9. Lock RB, Ross WE. DNA topoisomerases in cancer therapy. Anticancer Drug Des 1987;2:151-164.
10. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-342.
11. Reed JC. Bcl.2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Sem Hematol 1997;34:9.
12. Sato T, Hanada M, Bodrug S, et al. Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 1994;91:9238.
13. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-162.
14. Lautier D, Carritrot Y, Deeley RG. Multidrug resistance mediated by the multidrug resistance protein gene. Biochem Pharmacol 1996;52: 967.
15. Roninson IB, Abelson H, Horseman DE, Howell N. Amplification of specific DNA sequencies correlates with multidrug resistance in Chinese hamster cells. Nature 1984;309:626-628.
16. Arcecy RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993;81:2215-2218.
17. Gieseler F, NüBler V. Celular resistance mechanisms with impact on the therapy of multiple myeloma. Leukemia 1997;11(suppl 5): S1.
18. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS. P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. Blood 1993;81: 490-495.
19. Sonneveld P, Durie BG, Lokhorst HM. Modulation of multidrug resistance in multiple myeloma by cycloporin. Lancet 1992;340:255-259.
20. Sonneveld P, Schoester M, Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol 1994;12: 1584-1591.
21. Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, Kapel J, Groenewegen A, Charnick S, Zitoun R, Löwenberg B. Reversal of multidrug resistance by SDZ PSC 833 combined with VAD (vincristine, doxorrubicin, dexamethasone) in refractory multiple myeloma. A phase I study Leukemia 1996;10:1741-1750.
22. Nuessler V, Gieseler V, Gullis E, Pelka R, Stötzer O, Zwierzina H, Wilmmans W. Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progresive disease. Leukemia 1997;11(suppl 5):S10.
23. Chronic Leukemia-Myeloma Task Force, National Cancer Institute. Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 1973;4:145-147.
24. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842-854.
25. Bladé J, San Miguel JF, Alcalá A, Maldonado J, Sanz MA, García-Conde J, Moro MJ, Alonso C, Besalduch J, Zubizarreta A, Besses C, González Brito G, Hernández Martín J, Fernandez-Calvo J, Rubio D, Ortega F, Jiménez R, Colominas P, Faura MV, Font L, Tortosa J, Domingo A, Fontanillas M, Rozman C, Estapé C. Alternating combination VCMP/ VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol 1993;11:1165-1171.
26. Martínez A, San Miguel JF, Valverde B, Bárez A, Moro M, García-Marcos M, Pérez-Simón JA, Vidriales B, Orfao A. Functional expression of MDR1 in AML: Correlation with the clinical-biological, inmunophenotypical and prognostic disease characteristics. Ann Hematol 1997;75: 81-86.
27. Chaudhary PM, Roninson IB. Expression and activity od P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85-94.
28. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992;80:2735-2739.
29. Pérez-Simón JA, García-Sanz R, Tabernero MD, Almeida J, González M, Fernández-Calvo J, Moro MJ, Hernández JM, San Miguel JF, Orfäo A. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998;91: 3366-3371.
30. Pétriz J, García-Lopez J. Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia 1997;11:1124-1130.
31. Cornelissen JJ, Sonneveld P, Schoester M, Raaijmakers HGP, Nieuwenhuis HK, Dekker AW, Lokhorst HM. MDR-1 expression and response to vincristine, doxorubicin and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol 1994;12:115-119.
32. Dalton WS. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group Study. Cancer 1995;75:815-820.
33. Beck WT, Grogan TM. Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins. Leukemia 1997;11: 1107-1109.
34. Beck WT, Grogan T, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyet JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R. Methods to detect P-glycoprotein-associated multidrug resistance in patient tumors: consensus recomendations. Cancer Res 1996;56:3010-3020.
35. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreef M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992;80:2729-2734.
36. Okochi E, Iwahashi T, Tsuruo T. Monoclonal antibodies specific for P-glycoprotein. Leukemia 1997;11:1119-1123.
37. Ludescher C, Gattringer, Drach J, Hofmann J, Grunicke H. Rapid functional assay for the detection of multidrug-resistant cells using the fluorescent dye rhodamine 123. Blood 1991;78:1385-1387.
38. Ito Y, Tanimoto M, Kumazawa T, Okumura M, Morishima Y, Ohno R, Saito H. Increased P-glycoprotein expression and multidrug resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells. Sequential analysis of 15 cases at initial presentation and relapse stage. Cancer 1989;63:1534-1538.
39. Merkel DE, Fuqua SA, Tandon AK, Hill SM, Buzdar AU, McGuire WL. Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol 1989;7:1129-1136.
40. Tabernero D, San Miguel JF, García-Sanz R, Nájera L, García-Isidoro M, Pérez-Simón JA, González M, Wiegant J, Raap AK, Orfao A. Incidence of chromosome numerical changes in multiple myeloma: fluorencence in situ hibridization analysis using 15 chromosome-specific probes. Am J Pathol 1996;149:153-161.